This label expansion opens a new, underserved pediatric segment (ages 2-5) for ZORYVE, potentially driving incremental prescription volume and market share in pediatric psoriasis. Monitor upcoming quarterly earnings for commentary on pediatric adoption and any competitive responses from steroid-based alternatives. The approval also strengthens Arcutis' regulatory track record ahead of potential pipeline catalysts.
Price Chart
Executive Summary
Arcutis Biotherapeutics received FDA approval to expand ZORYVE cream 0.3% for plaque psoriasis to children as young as 2 years old, the seventh FDA approval for ZORYVE in four years. This addresses a significant treatment gap in pediatric psoriasis, where limited steroid-free options existed for young children. The approval is based on a Phase 2 MUSE study and long-term extension data showing safety and efficacy consistent with adult/adolescent trials.
Key Facts
- FDA approved sNDA for ZORYVE cream 0.3% to treat plaque psoriasis in children down to age 2, including intertriginous areas
- Seventh FDA approval for ZORYVE in four years; first once-daily steroid-free topical approved for ages 2+ with plaque psoriasis
- Approval based on 4-week MUSE study (ARQ-151-216) in children ages 2-5 and 24-week open-label extension (ARQ-151-306)
- ZORYVE cream 0.3% already approved for adults and children down to age 6; this expansion adds ages 2-5
- ZORYVE is the #1 prescribed branded topical therapy across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis combined
Financial Impact
Expands addressable pediatric plaque psoriasis population by approximately 2-5 year age group; no specific revenue figures provided in release
Risk Factors
- Competition from existing topical steroids and emerging non-steroidal therapies in pediatric psoriasis
- Reimbursement and formulary access for the expanded pediatric indication may take time to materialize
- Real-world adoption by pediatric dermatologists and primary care physicians may be slower than expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319348 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $24.86 $26.38 | ▲ +6.11% | ▲ +5.87% | $25.16 (+1.21%) |
Aug 21, 2026 6w ago | Insider Cluster | $25.08 $25.96 | ▲ +3.51% | ▲ +4.04% | $25.16 (+0.32%) |
Aug 19, 2026 6w ago | Insider Cluster | $25.35 $25.38 | ▲ +0.12% | ▲ +0.12% | $25.16 (−0.75%) |
Aug 11, 2026 7w ago | 144 | $26.28 $23.38 | ▼ −11.04% | ▼ −9.14% | $25.16 (−4.26%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 5, 2026 8w ago | Press Release | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 3, 2026 8w ago | 144 | $26.03 $23.75 | ▼ −8.76% | ▼ −7.52% | $25.16 (−3.34%) |
Jun 29, 2026 13w ago | Press Release | $26.22 $27.84 | ▲ +6.18% | ▲ +7.21% | $25.16 (−4.04%) |
Jun 18, 2026 15w ago | Insider Cluster | $26.21 $27.74 | ▲ +5.84% | ▲ +5.30% | $25.16 (−4.01%) |
Jun 9, 2026 16w ago | 8-K | $23.23 $28.78 | ▲ +23.89% | ▲ +20.27% | $25.16 (+8.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access